| Autor: |
Gavrilova, S., Kalyn, Ya., Safarova, T., Yakovleva, O., Sheshenin, V., Kornilov, V., Shipilova, E. |
| Předmět: |
|
| Zdroj: |
Neuroscience & Behavioral Physiology; Feb2017, Vol. 47 Issue 2, p138-147, 10p |
| Abstrakt: |
Objective. To carry out a comparative assessment of the efficacy and safety of monotherapy with a new-generation antidepressant (venlafaxin, agomelatine, or fluvoxamine) and complex antidepressant therapy using one of these antidepressants in combination with acetyl-L-carnitine (ALC, Carnicetin) for the treatment of depression in elderly patients in a gerontology psychiatric out-patients clinic. Materials and methods. Two groups of patients (aged 60-79 years) with mild or moderate depression, comparable in terms of the main demographic and clinical characteristics, received antidepressant mono- or complex (antidepressant and ALC) therapy for eight weeks. Results. The use of complex therapy including the neuroprotector Carnicetin, which has neurotrophic and energotropic mechanisms of action, was found to provide a faster-onset therapeutic response and a stronger effect than antidepressant monotherapy, which was supported by a significant reduction in depressive disorders, including measures of the severity of anxiety, along with improvements in the patients' cognitive functioning. Use of complex therapy was accompanied by a decrease in the frequency of adverse events. Conclusions. The results obtained here allow inclusion of Carnicetin into the complex antidepressant treatment to be recommended for use in gerontology psychiatric out-patient clinics. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink